Zanrè, V.; Bellinato, F.; Cardile, A.; Passarini, C.; Di Bella, S.; Menegazzi, M.
BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells. Int. J. Mol. Sci. 2024, 25, 11939.
https://doi.org/10.3390/ijms252211939
AMA Style
Zanrè V, Bellinato F, Cardile A, Passarini C, Di Bella S, Menegazzi M.
BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells. International Journal of Molecular Sciences. 2024; 25(22):11939.
https://doi.org/10.3390/ijms252211939
Chicago/Turabian Style
Zanrè, Valentina, Francesco Bellinato, Alessia Cardile, Carlotta Passarini, Stefano Di Bella, and Marta Menegazzi.
2024. "BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells" International Journal of Molecular Sciences 25, no. 22: 11939.
https://doi.org/10.3390/ijms252211939
APA Style
Zanrè, V., Bellinato, F., Cardile, A., Passarini, C., Di Bella, S., & Menegazzi, M.
(2024). BRAF-Mutated Melanoma Cell Lines Develop Distinct Molecular Signatures After Prolonged Exposure to AZ628 or Dabrafenib: Potential Benefits of the Antiretroviral Treatments Cabotegravir or Doravirine on BRAF-Inhibitor-Resistant Cells. International Journal of Molecular Sciences, 25(22), 11939.
https://doi.org/10.3390/ijms252211939
